{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T15:14:46Z","timestamp":1785683686310,"version":"3.56.0"},"reference-count":26,"publisher":"Georg Thieme Verlag KG","issue":"S 03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gesundheitswesen"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>\n          Hintergrund F\u00fcr die Surveillance von Diabetes bedarf es aktueller\n                    Daten zur Pr\u00e4valenz des Diabetes und seiner Komplikationen im zeitlichen\n                    Verlauf. Hierbei werden zunehmend Daten der gesetzlichen Krankenversicherung\n                    (GKV) genutzt, da diese zeitnah zur Verf\u00fcgung stehen und die Fallzahlen\n                    detaillierte Sch\u00e4tzungen auch von Diabeteskomplikationen erlauben. Ziel\n                    der vorliegenden Studie war die Entwicklung und interne Validierung von\n                    Falldefinitionen f\u00fcr die Pr\u00e4valenzsch\u00e4tzung der\n                    diabetischen Retinopathie (DRP), der diabetischen Polyneuropathie (DPN) und des\n                    diabetischen Fu\u00dfsyndroms (DFS).<\/jats:p><jats:p>\n          Methodik Datengrundlage der Studie bilden Personen mit Diabetes\n                    unterschieden nach Typ-1-, Typ-2- und sonstigem Diabetes in einer alters- und\n                    geschlechtsstratifizierten Stichprobe von Barmer Versicherten im Jahr 2018\n                    (n=72.744). Ausgehend von den zentralen ICD-Codes f\u00fcr die\n                    mikrovaskul\u00e4ren Komplikationen (DRP: H36.0; DPN: G63.2; DFS:\n                    E1X.74\/.75) wurden Falldefinitionen unter Einbezug weiterer ICD-Codes,\n                    die die Komplikation ohne direkten Diabetesbezug verschl\u00fcsseln,\n                    entwickelt. Anschlie\u00dfend wurden die Falldefinitionen intern validiert.\n                    Hierf\u00fcr wurden eine Codierung im station\u00e4ren (m1S) oder\n                    wiederholt im ambulanten Bereich (m2Q) sowie eine Codierung spezifischer\n                    Leistungen (EBM, OPS) und Arzneimittelverordnungen oder durch relevante\n                    Facharztgruppen betrachtet. Abschlie\u00dfend wurde das Vorliegen der\n                    Diagnosen in den Vorjahren analysiert.<\/jats:p><jats:p>\n          Ergebnisse Im Jahr 2018 betrug die Pr\u00e4valenz der zentralen\n                    ICD-Codes der DRP (H36.0) 8,4%, der DPN (G63.2) 18,9% und des\n                    DFS (E1X.74\/.75) 13,4%. Unter Einbezug weiterer ICD-Codes in die\n                    Falldefinitionen erh\u00f6hten sich die Pr\u00e4valenzen f\u00fcr DRP\n                    (9,6%) und DPN (20,7%) deutlich, f\u00fcr DFS kaum\n                    (13,5%). Die interne Validierung best\u00e4tigte den Gro\u00dfteil\n                    der Diagnosen (DRP: 96,7%; DPN: 96,5% DFS: 95,8%) und\n                    m2Q stellte das relevanteste Kriterium dar. Bei Ber\u00fccksichtigung von bis\n                    zu vier Vorjahren fielen die Pr\u00e4valenzen f\u00fcr DPN und DFS um bis\n                    zu 30% und f\u00fcr DRP um bis zu 64% h\u00f6her aus.<\/jats:p><jats:p>\n          Schlussfolgerung Der Einbezug zus\u00e4tzlicher ICD-Codes in die\n                    Falldefinition von mikrovaskul\u00e4ren Komplikationen des Diabetes erscheint\n                    sinnvoll, da diese die Sensitivit\u00e4t der\n                    Pr\u00e4valenzsch\u00e4tzung erh\u00f6ht. Die interne Validierung\n                    deutet darauf hin, dass die dokumentierten Diagnosen plausibel sind. Allerdings\n                    wird ein Teil der Diagnosen nicht j\u00e4hrlich dokumentiert, was zu einer\n                    Untersch\u00e4tzung in der querschnittlichen Betrachtung eines Jahres\n                    f\u00fchrt.<\/jats:p>","DOI":"10.1055\/a-2061-6954","type":"journal-article","created":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T22:36:47Z","timestamp":1685486207000},"page":"S196-S204","source":"Crossref","is-referenced-by-count":6,"special_numbering":"S","title":["Entwicklung und interne Validierung von Falldefinitionen f\u00fcr\n                    die Pr\u00e4valenzsch\u00e4tzung mikrovaskul\u00e4rer Komplikationen\n                    des Diabetes in Routinedaten"],"prefix":"10.1055","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7095-6567","authenticated-orcid":false,"given":"Lukas","family":"Reitzle","sequence":"additional","affiliation":[{"name":"Abteilung f\u00fcr Epidemiologie und Gesundheitsmonitoring, Robert\n                    Koch-Insitut, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"K\u00f6ster","sequence":"additional","affiliation":[{"name":"PMV forschungsgruppe an der Klinik f\u00fcr Kinder- und\n                    Jugendpsychiatrie und Psychotherapie, Medizinische Fakult\u00e4t und\n                    Uniklinik K\u00f6ln, Universit\u00e4t zu K\u00f6ln, K\u00f6ln,\n                    Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oktay","family":"Tuncer","sequence":"additional","affiliation":[{"name":"Abteilung f\u00fcr Epidemiologie und Gesundheitsmonitoring, Robert\n                    Koch-Insitut, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Abteilung f\u00fcr Epidemiologie und Gesundheitsmonitoring, Robert\n                    Koch-Insitut, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Meyer","sequence":"additional","affiliation":[{"name":"PMV forschungsgruppe an der Klinik f\u00fcr Kinder- und\n                    Jugendpsychiatrie und Psychotherapie, Medizinische Fakult\u00e4t und\n                    Uniklinik K\u00f6ln, Universit\u00e4t zu K\u00f6ln, K\u00f6ln,\n                    Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2023,5,30]]},"reference":[{"key":"ref1","volume-title":"Routinedaten im Gesundheitswesen: Handbuch Sekund\u00e4rdatenanalyse:\n                    Grundlagen, Methoden und Perspektiven. 2. Auflage","author":"E Swart","year":"2014"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s00125-022-05670-0","article-title":"Incidence of newly diagnosed diabetes after Covid-19","volume":"65","author":"W Rathmann","year":"2022","journal-title":"Diabetologia"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1055\/s-0030-1249688","article-title":"Interne Validierung von Diagnosen in GKV-Routinedaten: Konzeption mit Beispielen\n                    und Falldefinition","volume":"72","author":"I Schubert","year":"2010","journal-title":"Gesundheitswesen"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"54","DOI":"10.25646\/5982","article-title":"Sekund\u00e4rdaten in der Diabetes-Surveillance \u2013\n                    Kooperationsprojekte und Referenzdefinition zur dokumentierten\n                    Diabetespr\u00e4valenz","volume":"4","author":"C Schmidt","year":"2019","journal-title":"Journal of Health Monitoring"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.20364\/VA-17.03.","article-title":"Administrative Pr\u00e4valenzen und Inzidenzen des Diabetes mellitus von 2009\n                    bis 2015. Zentralinstitut f\u00fcr die kassen\u00e4rztliche Versorgung in\n                    Deutschland (Zi)","volume":"2017","author":"B Goffrier","year":"2017","journal-title":"Versorgungsatlas-Bericht Nr. 17\/03. Berlin"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00103-019-03068-9","article-title":"Pr\u00e4valenz und Inzidenz des dokumentierten Diabetes mellitus \u2013\n                    Referenzauswertung f\u00fcr die Diabetes-Surveillance auf Basis von Daten\n                    aller gesetzlich Krankenversicherten","volume":"63","author":"C Schmidt","year":"2019","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung\n                    Gesundheitsschutz"},{"key":"ref9","first-page":"177","article-title":"The Prevalence and Incidence of Diabetes in Germany: An Analysis of Statutory\n                    Health Insurance Data on 65 Million Individuals From the Years 2009 and\n                    2010","volume":"113","author":"T Tamayo","year":"2016","journal-title":"Deutsches \u00c4rzteblatt International"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e041508","DOI":"10.1136\/bmjopen-2020-041508","article-title":"Excess mortality in adults with documented diabetes in Germany: routine data\n                    analysis of all insurance claims in Germany 2013-2014","volume":"11","author":"C Schmidt","year":"2021","journal-title":"BMJ open"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3238\/arztebl.m2022.0314","article-title":"The burden of disease in Germany at the national and regional level \u2013\n                    results in terms of disability-adjusted life years (DALY) from the BURDEN 2020\n                    study","volume":"119","author":"M Porst","year":"2022","journal-title":"Dtsch Arztebl International"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s00103-020-03211-x","article-title":"Einsch\u00e4tzungen zur Pr\u00e4valenz mikrovaskul\u00e4rer\n                    Folgeerkrankungen bei Diabetes mellitus in Deutschland. Analyse von\n                    Versichertendaten aller gesetzlichen Krankenkassen f\u00fcr die Jahre 2012\n                    und 2013","volume":"63","author":"L Reitzle","year":"2020","journal-title":"Bundesgesundheitsblatt - Gesundheitsforschung -\n                    Gesundheitsschutz"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1055\/a-1791-0918.","article-title":"Algorithmus zur Unterscheidung von Diabetes mellitus Typ 1 und Typ 2 bei der\n                    Analyse von Routinedaten","author":"L Reitzle","year":"2022","journal-title":"Gesundheitswesen"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1055\/s-2006-939850","article-title":"Heterogenit\u00e4t der Kosten bei Patienten mit Diabetes mellitus: Die\n                    KoDiM-Studie","volume":"131","author":"I K\u00f6ster","year":"2006","journal-title":"Dtsch Med Wochenschr"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1007\/s00063-006-1050-8","article-title":"Kosten der antihyperglyk\u00e4mischen Behandlung des Diabetes mellitus","volume":"101","author":"L von Ferber","year":"2006","journal-title":"Medizinische Klinik"},{"key":"ref19","first-page":"131","volume-title":"Diabetes mellitus Typ 2. In. Stuttgart, Deutschland: Schattauer: Klauber J,\n                    G\u00fcnster C, Gerste B, Robra, BP, Schmake, N (Hrsg.) Versorgungs-Report\n                    2013\/2014 : Schwerpunkt: Depression","author":"N M\u00fcller","year":"2014"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1055\/s-0034-1375675","article-title":"Costs of Diabetes Mellitus (CoDiM) in Germany, direct per-capita costs of\n                    managing hyperglycaemia and diabetes complications in 2010 compared to 2001","volume":"122","author":"I Koster","year":"2014","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1186\/s12889-015-2188-1","article-title":"Prevalence, incidence and concomitant co-morbidities of type 2 diabetes mellitus\n                    in South Western Germany \u2013 a retrospective cohort and case control study\n                    in claims data of a large statutory health insurance","volume":"15","author":"M W Boehme","year":"2015","journal-title":"BMC Public Health"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1007\/s00125-011-2198-1","article-title":"Diabetic retinopathy in type 1 diabetes \u2013 a contemporary analysis of\n                    8,784 patients","volume":"54","author":"H P Hammes","year":"2011","journal-title":"Diabetologia"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e0132492","DOI":"10.1371\/journal.pone.0132492","article-title":"Risk Factors for Retinopathy and DME in Type 2 Diabetes-Results from the\n                    German\/Austrian DPV Database","volume":"10","author":"H P Hammes","year":"2015","journal-title":"PLoS One"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"16012","DOI":"10.1038\/nrdp.2016.12","article-title":"Diabetic retinopathy","volume":"2","author":"T Y Wong","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e000135","DOI":"10.1136\/bmjdrc-2015-000135","article-title":"Changes in diabetes care indicators: findings from German National Health\n                    Interview and Examination Surveys 1997-1999 and 2008-2011","volume":"3","author":"Y Du","year":"2015","journal-title":"BMJ Open Diabetes Res Care"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e0195426","DOI":"10.1371\/journal.pone.0195426","article-title":"Diabetic retinopathy screening in incident diabetes mellitus type 2 in Germany\n                    between 2004 and 2013 - A prospective cohort study based on health claims\n                    data","volume":"13","author":"D Kreft","year":"2018","journal-title":"PLoS One"},{"key":"ref28","volume-title":"Versorgungsreport Diabetes mellitus. 1. Auflage","author":"B Deckenbach","year":"2018"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1055\/a-1806-2115.","article-title":"Nutzung von Krankenkassenroutinedaten zur Bestimmung von\n                    Krankheitsh\u00e4ufigkeiten im Projekt BURDEN 2020","author":"K Sch\u00fcssel","year":"2022","journal-title":"Gesundheitswesen"},{"key":"ref31","first-page":"453","article-title":"Disease-Management-Programme f\u00fcr Diabetes mellitus Typ 2 in\n                    Deutschland","volume":"111","author":"S Fuchs","year":"2014","journal-title":"Dtsch Arztebl International"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1055\/s-0031-1275711","article-title":"Unterschiede in der Versichertenstruktur von Krankenkassen und deren\n                    Auswirkungen f\u00fcr die Versorgungsforschung: Ergebnisse des\n                    Bertelsmann-Gesundheitsmonitors","volume":"74","author":"F Hoffmann","year":"2012","journal-title":"Gesundheitswesen"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12874-020-01108-6","article-title":"The effects of different lookback periods on the sociodemographic structure of\n                    the study population and on the estimation of incidence rates: analyses with\n                    German claims data","volume":"20","author":"J Epping","year":"2020","journal-title":"BMC Med Res Methodol"}],"container-title":["Das Gesundheitswesen"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2061-6954.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T14:44:38Z","timestamp":1730817878000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2061-6954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,30]]},"references-count":26,"journal-issue":{"issue":"S 03","published-online":{"date-parts":[[2024,7,29]]},"published-print":{"date-parts":[[2024,7]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2061-6954","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0941-3790","1439-4421"],"issn-type":[{"value":"0941-3790","type":"print"},{"value":"1439-4421","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,30]]}}}